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Abstract: There is an increased interest in plasmid DNA as therapeutics. This is evident in the number
of ongoing clinical trials involving the use of plasmid DNA. In order to be an effective therapeutic,
high yield and high level of supercoiling are required. From the bioprocessing point of view, the
supercoiling level potentially has an impact on the ease of downstream processing. We approached
meeting these requirements through plasmid engineering. A 7.2 kb plasmid was developed by the
insertion of a bacteriophage Mu strong gyrase-binding sequence (Mu-SGS) to a 6.8 kb pSVβ-Gal
and it was used to transform four different E. coli strains, and cultured in order to investigate the
Mu-SGS effect and dependence on strain. There was an increase of over 20% in the total plasmid yield
with pSVβ-Gal398 in two of the strains. The supercoiled topoisomer content was increased by 5% in
both strains leading to a 27% increase in the overall yield. The extent of supercoiling was examined
using superhelical density (σ) quantification with pSVβ-Gal398 maintaining a superhelical density of
−0.022, and pSVβ-Gal −0.019, in both strains. This study has shown that plasmid modification with
the Mu-phage SGS sequence has a beneficial effect on improving not only the yield of total plasmid
but also the supercoiled topoisomer content of therapeutic plasmid DNA during bioprocessing.
Keywords: E. coli; plasmid bioprocessing; plasmid supercoiling; superhelical density; plasmid
engineering; nanoparticle tracking analysis (NTA)
1. Introduction
The past few decades have seen a rise in the focus of plasmid DNA for biotherapeutic production,
with applications including vaccines and gene therapy. The reasons include, but not exhaustively,
the ability to elicit both humoral and cell-mediated immune response [1–3] as well as the possibility
of having multiple protection from one preparation. The rise in the application of plasmid DNA for
vaccine and gene therapy is evident in ongoing clinical trials, with about 17.4% of all gene therapy
clinical trials involving plasmid DNA [4]. Although there are presently no approved DNA vaccines for
use in humans, there has been tremendous progress in the development of these vaccines, particularly
DNA vaccines targeting HPV-derived onco-antigens [5], and a number of completed clinical trials on
DNA vaccines for oncological indications which are extensively discussed in [6,7]. It is therefore no
surprise that this particular class of biomolecule is receiving such great attention.
An ample amount of plasmid DNA (pDNA) is required (in mg) because not all of it is integrated
during transfection and it must be mostly in the supercoiled form (in comparison to a linear and nicked
form) to be effective for biotherapeutic applications [8]. Therefore, two bioprocess challenges that
need to be addressed are the yield and the quality (i.e., maintaining a high supercoiled fraction) of the
plasmid DNA. Increasing the plasmid yield has been well studied, but there is minimal information
about increasing the supercoiling of the plasmid. A study carried out by Adamcik et al. highlighted
how temperature affects the distribution of topoisomers in plasmid preparation and the impact on
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supercoiling of the preparation [9]. For instance, it has been reported that by achieving a high cell
density culture, the plasmid yield is improved as plasmid production is directly linked to the biomass
yield of a culture [10]. Some of these reports have achieved high biomass yield by engineering the cell
using gene knockout or gene overexpression. Examples include the knockout of the pts gene responsible
for glucose transport and replacement with galp+ which codes for permease [11,12], modification of
pentose phosphate pathway [13], and knocking out the pyruvate kinase gene [14].
In addition, attempts have been made to modify culture media to achieve high plasmid yield.
O’Kennedy et al. [15] reported that at a specific ratio of carbon to nitrogen, the plasmid yield is increased.
Supplementation of optimized concentrations of glutamate and ammonium chloride have also been
reported to improve plasmid DNA production [16]. It has also been reported that a semi-defined
medium supplemented with casamino acid (SDCAS) supported high yield and plasmid stability as
compared with a medium containing soy amino acids and LB medium [15]. All of these reports
have tackled the plasmid yield, however, maintaining a high supercoiling is still a challenge that
needs addressing.
In addition to a high supercoiled amount being required for the effectiveness of plasmid use
for vaccine and gene therapy applications, it makes plasmid more compact as the plasmid becomes
coiled due to the twisting and writhing associated with supercoiling. This is potentially essential
for downstream processing of plasmid as these molecules are sensitive to shear during downstream
processes such as centrifugation, flow through pumps [17,18], and filtration. The sensitivity of plasmid
DNA to shear is also dependent on the size of the plasmid, hence by making plasmid more compact
we reduce the sensitivity on exposure to shear.
Several studies have investigated external factors and their effects on plasmid supercoiling [19–21].
However, there are very few reports that have investigated the effect of plasmid DNA modification
aimed at increasing supercoiling and superhelical density (measurement of the compactness of the
DNA) of the plasmid DNA [22]. The DNA negative supercoiling is introduced by the DNA gyrase,
a Type II topoisomerase that is tightly regulated alongside the DNA topoisomerase I, which relaxes
the DNA [23]. DNA gyrase overexpression in E. coli has only led to a slight increase in plasmid
supercoiling [24].
The catalytic activity of the DNA gyrase involves binding to a specific sequence on the DNA and
using energy from ATP to introduce a negative supercoil into the DNA [25]. Identifying the sequence
and exploiting the extent binding increases the rate at which gyrase introduces supercoils into the DNA.
A number of strong gyrase binding sites have been identified in plasmid pBR322, pSC101, and the
bacteriophage Mu. The Mu-phage gyrase binding sequence has been reported to have a strong affinity
for the binding of gyrase, hence stimulating the replication and packaging of the Mu bacteriophage in
its host [26]. This sequence is found in the middle of the 37 kb genome of the bacteriophage Mu and
contains an 8 bp sequence where the gyrase binds and inserts supercoil into the Mu genome [27].
Exploiting the efficiency of the Mu-phage SGS for increasing DNA supercoil and superhelical
density means increasing the supercoil nature of the plasmid further. Further studies have shown that
the length of the left and right of the key sequence on Mu-phage SGS also affects the efficiency of the
sequence to insert a supercoil into the plasmid DNA. In a separate study, Hassan et al. [22] tested
different lengths of the SGS and found that the 398 bp sequence, which is the longest of the different
SGS lengths tested, significantly increased the plasmid supercoiling and superhelical density of a 2.7
kb plasmid.
Several strains of E. coli have been selected for the production of plasmid DNA based on laboratory
use and commercial availability. These include E. coli K-12 strains such as JM108 [28], DH5α [11,15,29],
GALG20 [11], BL21(DE3) [30], SCS1-L [31], and DH10B [32]. Usually, host cells are selected based on
experiments carried out on the various strains available. Yau et al. [19] demonstrated that there is no
direct correlation between the strain and the plasmid, and therefore testing on different strains should
be carried out when selecting a strain for specific plasmids.
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In this study, we investigate the impact of the bacteriophage Mu strong gyrase binding site
sequence engineered into a 6.8 kb plasmid and amplified in four different E. coli strains which have been
selected based on past studies, as well as to examine the effect of the potential increase in supercoiling
on the integrity of the plasmid during downstream processing.
2. Materials and Methods
2.1. Strains amd Plasmids
The pSVβ-galactosidase plasmid vector was employed as the parent plasmid. The plasmid
contained the gene coding for ampicillin resistance which was used for its selection upon transformation
with a suitable host. The plasmid also contained the SV40 early promoter and enhancer sequence
that drove the transcription of a specific lacZ gene on the plasmid. The plasmid was purchased from
Promega Corporation (Southampton, UK). The Mu-phage SGS (strong gyrase-binding site) sequence
used in this project was as reported by Hassan et al. [22]. The 398 bp sequence was selected from
among the three sizes that were reported in the study. The selection of the sequence as a strong binding
site for the DNA gyrase in E. coli was based on the report by Pato and Banerjee [26]. The Mu-phage SGS
sequence was taken from the European Nucleotide Archive of the European Bioinformatics Institute
(EBI). The sequence was found on position 17,681 bp–18,078 bp of the 37 kb bacteriophage Mu genome.
The sequence was prepared as a synthetic gene and cloned into the plasmid vector by Genscript
Corporation (Genscript, Picastaway, NJ, USA). The resulting plasmid vector was named pSVβ-gal398.
The E. coli strains selected for this study were based on the studies of Yau et al. [19]. The strains
were also selected based on their industrial relevance and commercial availability. Several strains were
derivatives of the parent E. coli strain K-12. Table 1 shows the summary of the genotype of these strains.
All of the strains that were acquired in-house or commercially purchased, were then transformed with
plasmids pSVβ-Gal and pSVβ-Gal398 using a standard heat shock calcium chloride technique [33].
The cells were prepared as glycerol stocks and were transferred into cryovials and stored at −80 ◦C
until required.
Table 1. Strains selected for the study and their genotype.
Strain Genotype Source Status
BL-21 F− dcm hsdS
(
r−Bm
−
B
)
gal∆(DE3) [34] Commercial
DH5α
F− endA1 glnV44 thi−
1 recA1 relA1 gyrA96 deoR nupGΦ80dlacZ∆M15∆(lacZYA−
argF)U169, hsdR17
(
r−Km
+
K
)
,λ−
[35,36] Commercial
HB101
F−mcrB mrr hsdS20(rB−mB−)recA13leuB6ara
− 14 proA2 lacY1 galK2 xyl− 5 mtl
− 1 rpsL20(SmR) glnV44 λ−
[37] Non-commercial
W3110 F− λ− rph− 1 INV(rrnD, rrnE) [38] Non-commercial
The transformed cells, stored in glycerol, were thawed and used to streak LB agar (yeast extract,
5.0 g/L, tryptone 10.0 g/L, sodium chloride 5.0 g/L, and agar 15 g/L) plates which contained ampicillin
for the selection and growth of plasmid containing cells. The ampicillin concentration used was
100 µg/mL. The plates were then incubated at 37 ◦C for 24 h, wrapped in film, and stored at 4 ◦C until
they were required.
2.2. Fermentation
Two cultures (5 mL and 10 mL) containing LB media and the appropriate antibiotics (ampicillin)
were grown in 50 mL falcon tubes for 16 h at 37 ◦C in an incubator with an agitation speed of 250 rpm.
The media were inoculated with single picked colonies from freshly prepared agar plates. For shake
flask fermentation, the inoculum was prepared by inoculating 10 mL of culture from glycerol stock
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and incubating it in a shaker at 37 ◦C overnight. The overnight culture was used to inoculate 200 mL
of LB media containing ampicillin in a 1 L shake flask and placed in an orbital shaker at 37 ◦C with
an agitation speed of 250 rpm. For the 5 mL culture, samples were taken from the culture at the end
of the fermentation and the optical density (OD600nm) was measured with a spectrophotometer at a
wavelength of 600 nm. The OD was used to predict the biomass yield per mL of culture.
For the shake flask culture, samples were taken from the culture hourly and the optical density
was measured using a spectrophotometer with a wavelength of 600 nm. The OD was used to predict
the biomass yield per mL of culture. The optical density obtained was used to plot the growth curve of
the fermentation.
2.3. Plasmid Extraction and Purification
Plasmid DNA samples from the fermentation was extracted and purified using the Qiagen
Spin Mini Prep kits and the Qiagen Maxi prep kits (Qiagen Ltd, Sussex, UK). The procedure was
followed according to the protocols provided with the kits by the manufacturer. The plasmid yield
was determined by measuring the concentration of the plasmid DNA in the purified samples. The
concentration was determined by spectrophotometry using the Nanodrop ND-1000 Spectrophotometer
(Nanodrop, Willington, DE, USA).
2.4. Determination of Plasmid Topology
To determine the different topoisomers (linearized, open-circular, and supercoiled) of the plasmid
DNA present in the samples, linearized and open circular (also known as nicked) plasmid samples were
prepared and run alongside the samples during agarose gel electrophoresis. To prepare open-circular
plasmid, 2 µL of the enzyme Nt.Bst.NBI (NEB, UK) was added to a preparation of 2 µL plasmid DNA,
5 µL of 10X buffer, and 41 µL of water. The mixture was incubated at 55 ◦C for 1 h followed by
inactivation of the enzyme at 80 ◦C for 20 min. To prepare the linear plasmid, 2 µL of the enzyme
BamHI (NEB, UK) was added to the preparation of 2 µL plasmid DNA (equivalent to 1 µg), 5 µL of 10X
Cutsmart buffer, and 41 µL of water. The mixture was incubated at 37 ◦C for 15 min.
The plasmid DNA topology compositions and percentage intensities were determined using
agarose gel electrophoresis and 0.8% (w/v) agarose gel was prepared in 1X TAE (tris-acetate-EDTA)
buffer (Sigma-Aldrich, St. Louis, MI, USA). The gel was prestained with ethidium bromide (500 µg/mL)
and run in 1X TAE (tris-acetate-EDTA) buffer at 90 V for 2 h. The gel was viewed under a UV
light and the image was acquired using the AlphaImager Mini System (ProteinSimple, San Jose, CA,
USA). A subsequent method involved the use of SYBR® Gold which was used to stain the gel after
electrophoresis. The stained gel was viewed under blue fluorescence using the Amersham Imager 600
(GE Healthcare). The AlphaView CA Software (ProteinSimple, Version 3.4.0.0, San Jose, CA, USA) was
used to identify the bands and as a densitometry tool to quantify the intensity of the bands on the
acquired image of the gel.
2.5. Determination of Plasmid Superhelical Density
The plasmid super-helical density was determined using chloroquine agarose gel electrophoresis
with a slight modification of the method reported by Bowater [39]. Agarose (0.7% w/v) was prepared
in 1 × TBE (tris-borate-EDTA) buffer (Sigma Aldrich). Before running, 1.2 mg/L of chloroquine
diphosphate was used to prestain the gel. The sample was loaded, and electrophoresis was carried out
in the first dimension at 2 V/cm for 20 h with 1 × TBE containing the same concentration of chloroquine
diphosphate as the running buffer. The electrophoresis was stopped, and the gel was allowed to soak
in 1 × TBE buffer with 6 mg/L chloroquine diphosphate for 3 h. Electrophoresis was carried out in the
second dimension, 90◦ to the first at 1.8 V/cm for 24 h with 1 × TBE containing the same concentration
of chloroquine diphosphate in the soaking buffer as the running buffer. Gel was then rinsed three
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times in water for an hour each. The gel was stained with SYBR gold nucleic acid stain for 1 h before
visualization under a UV light. The superhelical density was calculated as follows:
σ =
∆Lk
Lko
(1)
Lko =
No
ho
(2)
where, ∆Lk is the linking difference determined from the gel image as the number of bands, Lko is the
linking number determined from the size of the plasmid in bp, N, and number of base pairs per each
helical turn assumed to be 10.5 bp.
2.6. Plasmid Shear Exposure Experiment
To carry out the shear experiments, the plasmids were diluted in TE buffer to a concentration
of 15–20 µg/mL. The ultra-scale down (USD) shear device was set to the maximum shear rate of
18,000 rpm (equivalent to 106 s−1). Then, 20 mL of the sample was injected into the USD shear device
while avoiding bubbles. With the exception of the controls, the sample was exposed to shear for 20 s,
as exposing the sample beyond this time had no effect on the plasmids [40]. After exposure to shear,
samples were collected and run on agarose gel electrophoresis to determine the percentage of supercoil
content. The supercoiled content was expressed as a fraction of the supercoiled content of the control.
2.7. Plasmid Hydrodynamic Diameter
The plasmid hydrodynamic diameter (Dh) was determined using the nanoparticle tracking
analysis (NTA). This was done using the Nanosight NS300 (Malvern Instrument, UK). Using an inlet
syringe pump, 1 mL of sample prepared in filtered TE buffer was injected into the sample chamber. The
laser module was then mounted, and the camera started. Once the recording was complete, standard
measurement tracking analysis was carried out in triplicate and the average recorded on the NTA
software. The output showed the distribution of particles in the sample with mean size and modal size
recorded. A detailed protocol is reported in [41].
3. Results
3.1. Effects of SGS on Plasmid Yield and Supercoiling and Strain Selection
Figure 1 shows the results observed for the four different strains selected with respect to the plasmid
yield and supercoil topoisomer content of the extracted plasmid. A similar fermentation approach was
implemented on the four strains as detailed in the materials and methods. Results are the average of the
triplicates for each strain-plasmid combination. The biomass yield is reported as OD600nm. All results
were subjected to statistical analysis to test for significantly different observations. A significantly
higher plasmid yield was observed for SGS-containing plasmid pSVβ-gal398 as compared with the
parent plasmid pSVβ-gal. The increase plasmid yield for pSVβ-gal398 was observed in the strains
DH5α and HB101 with an increase of 36% and 27%, respectively, as compared with pSVβ-gal (p < 0.05
when subjected to a t-test between the two plasmids in each strain, however this was not the case for
the other two strains W3110 and BL21(DE3).
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Figure 1. Plasmid yield and supercoiling of pSVβ-gal398 (pSV-SGS) and pSVβ-gal (pSV) amplified in
the four strains. All analyses were done in triplicates. (a) The total plasmid yield (mg/L) of pSVβ-gal398
and pSVβ-gal amplified in the four strains and (b) percentage supercoiled topoisomer content of
plasmid extracted from the four strains used. The differences observed were tested statistically with
p < 0.05.
The supercoiled content was determined according to the method describe in the materials and
method section. The supercoil percentage shown in the figure is expressed as mean of triplicates ±
SEM the differences observed was subjected to a paired t-test with a confidence limit of 95%. Similar to
the plasmid yield discussed above, a high supercoiled content was observed in DH5α and HB101 with
supercoiled content for both SGS-containing plasmid and non-SGS plasmid exceeding 90% as shown
in Figure 1B. However, there was a statistically significant increase (5%) in the supercoiled content for
pSVβ-gal398 as compared with the parent plasmid pSVβ-gal (p-value < 0.05 in both strains).
Figure 2A shows results of the shake flask fermentation growth curve for E. coli strains DH5α and
HB101 harboring pSVβ-gal398 and pSVβ-gal. Fermentations were run in triplicates. Figure 2B shows
a plot of plasmid yield for E. coli strains DH5α and HB101 harboring pSVβ-gal398 and pSVβ-gal. The
differences observed between the two plasmids for each strain are statistically significant as it was
subjected to a t-test with a confidence limit of 95% (p < 0.05). The plasmid yield differences observed
between the two strains were not statistically significant when subjected to a statistical test (p > 0.05).
Figure 2. Characteristics of shake flask fermentation of the two strains HB101 and DH5α. Charts show
(a) growth curve of the strains bearing both the non-SGS plasmid and SGS containing plasmid and
(b) plasmid yield of pSVβ-gal398 and pSVβ-gal amplified in the two strains. Results are the mean of
triplicate samples (n = 3).
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3.2. Effect of SGS Presence on the Superhelical Density of the Plasmid
Figure 3a shows a DH5α sample two-dimensional and one-dimensional chloroquine agarose gel
which was run to determine the linking difference of the plasmid. Each sample was run on a single gel,
hence it is impossible to show all sample gels. Each band represents the different level of supercoil that
is found on the plasmid. The linking difference with the linking number was used to calculate the
superhelical density of the plasmid according to the equations in materials and methods. The result
for triplicate samples was taken. Figure 3B shows the result of the comparison of the superhelical
density of the two plasmids (pSVβ-gal398 and pSVβ-gal) amplified in the two strains HB101 and
DH5α expressed as mean ±SEM. As shown in the graph, the superhelical density of pSVβ-gal398 was
approximately −0.022 in both strains as compared with −0.019 for pSVβ-gal (with p < 0.05).
Figure 3. Superhelical density determination of plasmid amplified in DH5α and HB101. (a) 2D and 1D
chloroquine-agarose gel electrophoresis showing the distribution of topoisomers of the plasmid. The
bands depict the linking difference which is then used to calculate the superhelical density (b) Chart
showing the superhelical density of pSVβ-gal398 and pSVβ-gal amplified in the two strains. N = 4.
The difference observed is statistically significant in the two strains (p < 0.05).
3.3. Impact of Increase Supercoiling on Plasmid Integrity
The plasmid integrity was determined by measuring the supercoiled content of plasmid
preparation when exposed to shear. Details of the experiment are in the materials and method
section. The shear stress is expressed as the energy dissipation rate and the supercoiled fraction was
determined. Figure 4 shows the plot of supercoiled fractions for the two plasmids in each strain. The
supercoiled fraction was determined by comparing the supercoiled content of the sheared plasmid
relative to the control (non-sheared sample) and expressed as a percentage of the control. Supercoiled
fractions are reported as mean ± SEM. Despite both plasmids maintaining a supercoiled fraction above
90%, there was a higher supercoiled fraction in the plasmid bearing SGS. The differences observed
between the plasmid for each strain are statistically significant with a p-value <0.05 and a confidence
limit of 95%. This observation is not surprising as it has been reported that plasmid <13 kb are affected
minimally by shearing during downstream processing with significant shear observed for plasmid
larger than 13 kb [17,18]. Figure 4c shows the gel image of the sheared plasmid and quantification
carried out by densitometric method. Most of the sheared plasmid end up as nicked topology as
labelled in the figure.
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Figure 4. (a) Supercoiled topoisomer content after exposure to shear using the USD shear device,
expressed as a fraction of the control (supercoiled content of non-sheared sample), n = 3 (b) Supercoiled
content of the control sample before shearing. (c) Gel image of the samples after shearing. M =
marker, Lane 1 = DH5α/pSVβ-gal398 control sample, Lane 2–4 = DH5α/ pSVβ-gal398 sheared samples,
Lane 5 = DH5α/pSVβ-gal control sample, Lane 6–8 = DH5α/pSVβ-gal sheared samples, Lane 9 =
HB101/pSVβ-gal398 control sample, Lane 10–12 = HB101/pSVβ-gal398 sheared samples, Lane 13=
HB101/pSVβ-gal control sample, Lane 14–16 = HB101/ pSVβ-gal sheared samples, N = nicked plasmid,
and S = supercoiled plasmid.
3.4. Determination of Plasmid Compactness by Particle Hydrodynamic Diameter Measurement
Figure 5 shows the results of plasmid hydrodynamic diameter determination using the nanoparticle
tracking analysis (NTA) in an attempt to measure the determine plasmid compactness by size
measurement. The NTA measures polydisperse particles and Figure 5c,d show the distribution of
plasmid in a sample preparation of pSVβ-gal398 and pSVβ-gal amplified in HB101. The peaks are
the concentration (particles/mL) of the different isoform of plasmid present in the preparation. The
mode of the distribution was used in the analysis as it was expected that most of the plasmid particles
were in the supercoiled form. It was confirmed from the densitometry method that the majority
of the plasmids were in the supercoiled form. In order to confirm this from the NTA analysis, the
hydrodynamic diameter of the nicked and linear plasmid was measured for comparison. Figure 5a
shows the hydrodynamic diameter of linearized and nicked pSVβ-gal398. The hydrodynamic diameter
is expressed as mean± SEM of the triplicate samples. Figure 5b shows a plot of the sizes of pSVβ-gal398,
pSVβ-gal linear, and nicked plasmid amplified in strains HB101 and DH5α. The results are mean
±SEM of the triplicate samples. The summary of the hydrodynamic diameter is shown in Table 2. The
result shows that pSVβ-gal398 is more compact with a lower hydrodynamic diameter as compared
with pSVβ-gal in both strains used.
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Figure 5. Particle size determination using the nanoparticle tracking analysis which tracks particle
based on Brownian motion. Charts showing (A) the hydrodynamic diameter (Dh) of linearized and
nicked pSVβ-gal398 plasmid and (B) the hydrodynamic diameter of supercoiled plasmid pSVβ-gal398
and pSVβ-gal in the two strains. The sizes are compared to the nicked and linearized plasmid which
are larger than the supercoiled form of the plasmid. (C) and (D) show the particle size distribution of
the plasmid pSVβ-gal398 and pSVβ-gal from the strain DH5α. It shows the plot of diameter against
concentration in particles/mL. The analyses were done in triplicate for all samples.
Table 2. Superhelical density and hydrodynamic diameter of the plasmids amplified in different strains.
The hydrodynamic diameter is expressed as mean + SEM and n = 3.
HB101 DH5α
pSVβ-gal398 pSVβ-gal pSVβ-gal398 pSVβ-gal
Superhelical density −0.0218 −0.0192 −0.0204 −0.0185
Hydrodynamic diameter 39.53 ± 6.52 nm 70.77 ± 8.84 nm 56.97 ± 1.55 nm 85.50 ± 7.19 nm
Compactness 44% more compact 34% more compact
4. Discussion
As a result of the progress in some clinical trials involving DNA vaccines, it is expected that
these DNA therapeutics will be ready for human use in the next few years [5–7]. This means that a
Bioengineering 2019, 6, 54 10 of 16
cost-effective production platform needs to be ready for mass production. A cost-effective platform
would include a high yield and high supercoiled plasmid producing process. Supercoiling is essential
for the application of DNA as vaccines and for gene therapy applications. DNA supercoiling is
important for processes such as replication, transcription [42], as well as unknotting and decatenation
of double stranded DN which are both required for efficient DNA metabolism [43]. Studies have
investigated the impact of supercoiling on the efficacy of vaccine with one report suggesting a plasmid
preparation containing above 70% supercoiled topoisomer is capable of inducing immunity compared
to the open circular topoisomer and linear topoisomer [8]. In addition, the FDA recommends that
plasmid preparation should contain >80% supercoiled fraction, and the expectation of the bioprocess
industry is that plasmid preparation should contain >90% supercoiled content [44]. Hence, it is
important to focus on increasing both the yield and the supercoiled topoisomer of plasmid preparation
to meet the expected production of therapeutic DNA products.
We have previously identified that a 398 bp Mu-phage SGS induces supercoiling of plasmid
DNA [22]. In this study, the 398 bp Mu-phage SGS sequence was introduced into a 7.2 kb plasmid
pSVβ-gal. The study was carried out in small-scale with different strains of E. coli transformed with
the SGS and non-SGS containing plasmids. The aim of investigating different strains was to observe
the dependency of Mu-SGS on the host strain and to select the best-behaving strain(s). The selected
strains were based on the previous report by Yau et al. [19] who reported that plasmid amplification
and optimization is host-strain dependent. Therefore, we studied how much impact the host strain
would have on the amplification of the recombined plasmid.
There was a high plasmid yield observed in two of the strains used (HB101 and DH5α) for plasmid
bearing SGS (pSVβ-gal398). The high plasmid yield observed in DH5α agrees with the review of Lara
and Ramirez [10], highlighting DH5α as a high plasmid yield producing strain specifically designed
for plasmid production. HB101 on the other hand has not been extensively employed for plasmid
production, most likely due to its high carbohydrate contents which may cause problems during
downstream processing [45], however there are a few studies who have reported high plasmid yield
using this strain of E. coli [19,46]. The significance of the increase in plasmid yield is implicated in the
overall plasmid yield which is reported to be around 65% for a plant designed to produced 141 g per
batch [47].
The supercoiled topoisomer content was also considered for strain-dependence amplification of
the SGS-containing plasmid, as this is one of the bioprocess requirement for plasmid DNA production
for therapeutic application [48]. Similar to the plasmid yield discussed above, a high supercoiled
content was observed in DH5α and HB101, with supercoiled content for both SGS-containing plasmid
and non-SGS plasmid exceeding 90%, as shown in Figure 1B. However, there was a statistically
significant increase (5%) in the supercoiled content for pSVβ-gal398 as compared with the parent
plasmid pSVβ-gal (p-value < 0.05 in both strains). This shows the impact of the presence of the
Mu-phage SGS sequence which has been reported to increase the supercoiling of DNA due to strong
binding of the gyrase [22,49]. The binding of the gyrase to the SGS site induces a nick on the plasmid
and enhances supercoiling of the plasmid [24,50,51]. The enhancement of supercoiling is shown by
the increased superhelical density of the plasmid which is discussed later. A large proportion of the
preparation in BL21(DE3) was nicked, as shown in Figure 1B. This shows again that the effect of SGS
presence on the supercoiling of the plasmid DNA is strain dependent. A similar result was observed
for W3110.
Therefore, on the basis of the result of the initial screening studies on the strains, we selected the
two best-behaving strains for further study. The increase in the amount of supercoiled plasmid in
the preparation coupled with the increase in plasmid yield further led to an increase in the overall
productivity with a 27% for pSVβ-gal398 as compared with the unmodified pSVβ-gal.
Figure 2 shows the results of the shake flask fermentation growth curve for E. coli strains DH5α
and HB101 harbouring pSVβ-gal398 and pSVβ-gal. The final biomass yield observed agreed with
initial studies with no significant differences between host strain harbouring pSVβ-gal398 and strain
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harbouring pSVβ-gal. We did not expect that there would be a significant difference although the
presence of the extra SGS sequence in the pSVβ-gal398 could have added to the metabolic stress on
the strain [52], but since it was not expressing any additional recombinant product, the effect would
be minimal. However, there was a lower growth rate observed in the strain HB101 but not in DH5α.
The presence of the extra sequence on the plasmid may have led to the reduced growth rate observed
particularly in HB101 [53]. In addition, the differences in the genotype of both strains may have played
a role in the differences observed in the growth curve, for example, DH5α contained a gyrA96 mutation
in the gyrase gene [54]. This mutation may have played a role in the differences observed. The fact
that the decrease in growth rate was observed only in HB101 reiterates the reports that bioprocessing
of plasmid DNA is strain dependent [19].
The plasmid yield was observed to be higher for pSVβ-gal398 in both the strains 7.63 mg/L and
7.44 mg/L in HB101 and DH5α, respectively as compared with the parent plasmid pSVβ-gal with a
yield of 6.59 mg/L and 6.38 mg/L in HB101 and DH5α, respectively. The increase in plasmid yield
was as a result of an increase in plasmid copy number (not shown). The plasmid copy number was
investigated as it was clear that the observed increase in plasmid yield was not due to an increase in
biomass yield, as the final biomass was similar for the strain-plasmid combinations for the two E. coli
strains investigated. The increase in copy number may have been influenced by the presence of SGS
on the plasmid, however, this needs further investigation. Another possible reason for the increase
in plasmid yield, specifically in HB101, may be the low growth rate, because a low growth rate has
been reported to support plasmid amplification [48]. When comparing the two strains carrying the
modified plasmid, the differences in the plasmid yield observed may again be as a result of the gyrA96
mutation in DH5α which is not present in HB101.
Having established the significance of SGS on the yield and supercoiling of plasmid, we set out
to determine the extent of supercoiling by determining the superhelical density (σ) of the plasmid.
This is a measure of how supercoiled a plasmid is in terms of the twist (that is the winding of the
DNA helix around its axis) and writhe (the number of times the DNA helix crosses itself) of the
two strands on one another [55]. The superhelical density of DNA also measures if the DNA is
positively supercoiled or negatively supercoiled. This is determined using the linking number, which
quantitatively describes the topology of the plasmid in terms of twist and writhe. With the exception
of extreme thermophiles [51], negatively supercoiled DNA is the most preferred topological form of
DNA as it facilitates the interaction between replication/transcriptional proteins and DNA [56]. As
shown in Figure 3, the superhelical density of pSVβ-gal398 was approximately –0.022 in both strains
as compared with –0.019 for pSVβ-gal (p < 0.05). This agrees with earlier report by Hassan et al [22]
who observed the same result in a 2.8 kb plasmid. However, as this was a small-sized plasmid, it
was necessary to investigate if this effect was observed for a medium-sized plasmid, as plasmids for
therapeutic applications are likely to be in the range of >6 kb
The increase in superhelicity or superhelical density observed in plasmid carrying the SGS sequence
translates to high negative supercoiling. The implication of the high superhelicity to bioprocessing
challenges is the possibility of maintaining the integrity of the plasmid during downstream unit
operations such as centrifugation and filtration as they would be more compact and less sensitive to
shear [17,57]. Moreover, it has been reported that supercoiling is essential for efficient transfection [58].
Therefore, the increase in superhelicity of the plasmid could potentially increase the transfection
efficiency of the plasmid [58–60]. The increase in superhelical density is equivalent to an average of
two extra linking number differences (∆Lk) in pSVβ-gal398 compared to pSVβ-gal. However, both
plasmids are negatively supercoiled.
One of the potential benefits of a highly supercoiled plasmid is the maintenance of plasmid
integrity during downstream processing due to its high compactness [57]. Plasmid DNA molecules
are exposed to elongational shear stress during the centrifugation process as well as in pumps [17,18].
Shear stress causes nicking of the plasmid hence reducing the supercoiled plasmid topoisomer content
of the final plasmid preparation. We tested how pSVβ-gal398 behaves when exposed to shear since the
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higher superhelical density means it is more compact. The results showed that there was a reduction
in the supercoiled content of pSVβ-gal as compared with pSVβ-gal398. The supercoiled content of
plasmid pSVβ-gal398 remained intact despite exposing them to shear, although the supercoiled content
of the two plasmids preparation was not less than 90%. This observation is not surprising as it has been
reported that plasmid with a size of <13 kb are affected minimally by shearing during downstream
processing with significant shear observed for plasmid larger than 13 kb [17,18]. The maintenance of
integrity could be attributed to the increase in compactness of the plasmid [57].
An attempt was made to quantify the compactness of the plasmid by determining the
hydrodynamic diameter of the plasmids. Conformational changes induced by SGS presence were
determined by measuring the hydrodynamic diameter of the plasmid using nanoparticle tracking
analysis (NTA). The NTA measures the hydrodynamic diameter based on the diffusion coefficient of
the particle in Brownian motion and then tracks the particle to establish the diameter of the particle.
It is able to track single particles with high resolution and detect both high and small particles
simultaneously [61]. In addition, NTA is able to measure the concentration of particles in solution [62].
The plasmid hydrodynamic diameter (Dh) was determined using the Nanosight NS300 (Malvern,
UK) and both the plasmids pSVβ-gal and pSVβ-gal398 amplified in the strains HB101 and DH5α
were examined.
Figure 5 shows the average hydrodynamic diameter of the linear and nicked plasmid. It is
expected that the nicked plasmid will be larger than the linear plasmid as it has been observed during
gel electrophoresis that supercoiled plasmid will migrate the fastest due to its tight packing, followed
by linear plasmid, with the nicked plasmid migrating the slowest. The supercoiled plasmid is, therefore,
expected to have a smaller size relative to linear and nicked plasmid. The hydrodynamic diameter
observed also highlighted the compactness of the pSVβ-gal398 as ccompared with pSVβ-gal. For
plasmids amplified in the E. coli strain HB101, the modal hydrodynamic diameter for the pSVβ-gal398 is
40 nm while the modal hydrodynamic diameter of the pSVβ-gal is 70 nm (Figure 5B). This supports the
observation from the two-dimensional chloroquine agarose gel electrophoresis, where the superhelical
density of pSVβ-gal398 was found to be higher than pSVβ-gal. The same was observed for plasmids
amplified in the E. coli strain DH5α where the modal hydrodynamic diameter of the pSVβ-gal398 and
pSVβ-gal were observed to be 57 nm and 86 nm, respectively (Figure 5B). This observation agrees
with result observed during the measurement of superhelical density where pSVβ-gal398 had a higher
superchelical density and hence more compact. The compactness observed is attributed to the presence
of the Mu-SGS on the plasmid as reported earlier. This study highlights the possibility of investigating
plasmid DNA hydrodynamic size using the nanoparticle tracking analysis (NTA) and to further prove
the influence of Mu-SGS presence on the compactness of the plasmid DNA which are requirements for
DNA uses for therapeutic applications.
Surprisingly, the effect of Mu-SGS on plasmid supercoiling was observed to be more prominent in
plasmids amplified in HB101 in comparison to DH5α, a common E. coli strain for plasmid production.
Although, there was an impact of Mu-SGS on the plasmid in both strains, the superhelical density and
plasmid hydrodynamic diameter (Dh) show that the plasmids amplified in HB101 are more compact
and supercoiled than plasmids amplified in DH5α (Table 2). The possible explanation goes back to the
differences in genotype, and in particular the gyrA96 mutation, as there is a direct interaction between
DNA gyrase and the Mu-SGS. This mutation could be limiting the activity of the DNA gyrase on
the Mu-SGS due to conformational changes induced by the mutation. This is also evident from the
investigation of the effect of shear. As shown in Figure 4, pSVβ-gal398 amplified in HB101 were more
resistant to shear effect assuming a 100% maintenance of integrity after exposure to shear. Yau et al. [19]
reported a strain dependency on plasmid production. This study further emphasizes the selection of
the right strain for specific plasmid during bioprocessing.
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5. Conclusions
The results of this study show that the yield and extent of supercoiling in plasmid is improved by
modifying the plasmid, as supercoiling is required for the application of plasmid as biotherapeutics.
By increasing the supercoiling, the overall yield of supercoiled plasmid is increased significantly, hence,
solving the bioprocess challenge of plasmid yield and quality. We also showed that the effect of SGS is
not limited to a 2.8 kb plasmid as we reported earlier [22]. Increasing the supercoiling also increases
the compactness of the plasmid. This is potentially beneficial during downstream processing as an
increase in compactness reduces the nicking of plasmid caused by shear exposure.
We also reported that the effect of Mu-SGS to improve the supercoiling of the plasmid DNA is
strain dependent, since the effect was more pronounced in strain HB101 as compared with DH5α.
Although DH5α has been widely adopted as a favourite for plasmid production, there is an opportunity
for adopting HB101 as a choice of strain. The extent of supercoiling was quantified by measuring the
superhelical density of the DNA, a term which employs the linking difference of the plasmid.
To investigate the effect of the Mu-SGS presence on the overall compactness, the hydrodynamic
diameter of the plasmid was measured using nanoparticle tracking analysis (NTA). This method
was used over the dynamic light scattering (DLS) method because it employs a number-weighted
measurement rather than an intensity-weighted average of the DLS. The number-weighted
measurement is more reliable as the plasmid preparation is polydispersed. The supercoiled plasmid
hydrodynamic diameter was compared to the linearized and nicked plasmids. The results from the
NTA also confirmed that the Mu-SGS containing plasmid was more supercoiled compared to the
parent plasmid, further strengthening the observations with the superhelical density determination.
The study also highlights the possibility of quantifying the extent of plasmid supercoiling using the
nanoparticle tracking analysis (NTA).
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